These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 25527215)

  • 1. Imaging atlas for eligibility and on-study safety of potential joint adverse events in anti-NGF studies.
    Roemer FW; Guermazi A
    Osteoarthritis Cartilage; 2015 Jan; 23 Suppl 1():S1-2. PubMed ID: 25527215
    [No Abstract]   [Full Text] [Related]  

  • 2. Imaging atlas for eligibility and on-study safety of potential knee adverse events in anti-NGF studies (Part 1).
    Roemer FW; Hayes CW; Miller CG; Hoover K; Guermazi A
    Osteoarthritis Cartilage; 2015 Jan; 23 Suppl 1():S22-42. PubMed ID: 25527217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging atlas for eligibility and on-study safety of potential hip adverse events in anti-NGF studies (Part 2).
    Roemer FW; Hayes CW; Miller CG; Hoover K; Guermazi A
    Osteoarthritis Cartilage; 2015 Jan; 23 Suppl 1():S43-58. PubMed ID: 25527219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging atlas for eligibility and on-study safety of potential shoulder adverse events in anti-NGF studies (Part 3).
    Roemer FW; Hayes CW; Miller CG; Hoover K; Guermazi A
    Osteoarthritis Cartilage; 2015 Jan; 23 Suppl 1():S59-68. PubMed ID: 25527220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The current status of imaging in anti-NGF clinical trials.
    Miller CG; Guermazi A; Roemer F
    Osteoarthritis Cartilage; 2015 Jan; 23 Suppl 1():S3-7. PubMed ID: 25527218
    [No Abstract]   [Full Text] [Related]  

  • 6. Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies.
    Hochberg MC
    Osteoarthritis Cartilage; 2015 Jan; 23 Suppl 1():S18-21. PubMed ID: 25527216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term analgesic effect of a single dose of anti-NGF antibody on pain during motion without notable suppression of joint edema and lesion in a rat model of osteoarthritis.
    Ishikawa G; Koya Y; Tanaka H; Nagakura Y
    Osteoarthritis Cartilage; 2015 Jun; 23(6):925-32. PubMed ID: 25677108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain.
    Miller RE; Malfait AM; Block JA
    Clin Exp Rheumatol; 2017; 35 Suppl 107(5):85-87. PubMed ID: 28967370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The fine line between innovation and risk : Is anti-NGF a pain medication of the future?].
    Schaible HG
    Schmerz; 2010 Dec; 24(6):559-60. PubMed ID: 21057818
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting nerve growth factor (NGF) for pain management: what does the future hold for NGF antagonists?
    Bannwarth B; Kostine M
    Drugs; 2014 Apr; 74(6):619-26. PubMed ID: 24691709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nerve growth factor blockade for the management of osteoarthritis pain: what can we learn from clinical trials and preclinical models?
    Miller RE; Block JA; Malfait AM
    Curr Opin Rheumatol; 2017 Jan; 29(1):110-118. PubMed ID: 27672741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologics in the treatment of chronic pain: a new era of therapy?
    Bannwarth B; Kostine M
    Clin Pharmacol Ther; 2015 Feb; 97(2):122-4. PubMed ID: 25670514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Monoclonal Antibodies against Nerve Growth Factor on Healthy Bone and Joint Tissues in Mice, Rats, and Monkeys: Histopathologic, Biomarker, and Microcomputed Tomographic Assessments.
    Gropp KE; Carlson CS; Evans MG; Bagi CM; Reagan WJ; Hurst SI; Shelton DL; Zorbas MA
    Toxicol Pathol; 2018 Jun; 46(4):408-420. PubMed ID: 29768985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re: Re: Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs.
    Werts A; Reece D; Simon T; Cole P
    Vet J; 2024 Aug; 306():106175. PubMed ID: 38885831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor.
    Eibl JK; Strasser BC; Ross GM
    Neurochem Int; 2012 Dec; 61(8):1266-75. PubMed ID: 23103525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies to nerve growth factor reverse established tactile allodynia in rodent models of neuropathic pain without tolerance.
    Wild KD; Bian D; Zhu D; Davis J; Bannon AW; Zhang TJ; Louis JC
    J Pharmacol Exp Ther; 2007 Jul; 322(1):282-7. PubMed ID: 17431136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nerve growth factor and nociception: from experimental embryology to new analgesic therapy.
    Lewin GR; Lechner SG; Smith ES
    Handb Exp Pharmacol; 2014; 220():251-82. PubMed ID: 24668476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Analgesic arthropathy].
    Zbojanová M; Trnavský K; Schultz P
    Fysiatr Revmatol Vestn; 1982 Jan; 60(1):17-20. PubMed ID: 7200064
    [No Abstract]   [Full Text] [Related]  

  • 19. Sciatic nerve regeneration is not inhibited by anti-NGF antibody treatment in the adult rat.
    Lankford KL; Arroyo EJ; Liu CN; Somps CJ; Zorbas MA; Shelton DL; Evans MG; Hurst SI; Kocsis JD
    Neuroscience; 2013 Jun; 241():157-69. PubMed ID: 23531437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of neurotrophin signaling by monoclonal antibodies.
    Rosenthal A; Lin JC
    Handb Exp Pharmacol; 2014; 220():497-512. PubMed ID: 24668485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.